Background The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Background: Mavacamten, an orally administered, small-molecule modulator of cardiac
myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic …

Abstract Background: The HCMR (Hypertrophic Cardiomyopathy Registry) is a National
Heart, Lung, and Blood Institute–funded, prospective registry of 2,755 patients with …

Abstract Background EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461]
in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) demonstrated that …

Hypertrophic cardiomyopathy (HCM) is often caused by pathogenic variants in sarcomeric
genes and characterized by left ventricular (LV) hypertrophy, myocardial fibrosis and …

Background: Hypertrophic cardiomyopathy is the leading cause of sudden cardiac death
(SCD) in children and young adults. Our objective was to develop and validate a SCD risk …

Hypertrophic cardiomyopathy (HCM) was traditionally described as an autosomal dominant
Mendelian disease but is now increasingly recognized as having a complex genetic …

Importance Whether vigorous intensity exercise is associated with an increase in risk of
ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown …

Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused
by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility …

Background: The term “end stage” has been used to describe hypertrophic cardiomyopathy
(HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when left …